Skip to main content
. 2020 Dec 5;59(Suppl 5):v52–v62. doi: 10.1093/rheumatology/keaa404

Table 3.

Unmet needs in NPSLE

Diagnostic biomarkers for determining the attribution of NP events to SLE
 Potential candidates: CSF and serum proteins, neuroimaging
Novel therapies for NPSLE
 Potential targets: BBB, pro-inflammatory cytokines, microglia
Advancing clinical trials for NPSLE.
 Potential options: drugs for non-emergent NP events (e.g. mood disorders), validate outcome measures (e.g. self-report instruments, neuroimaging for brain structure and function)